GlassScriptPhysician profile
Joy L Barnes
NPI 1255591327
$748.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2020: $371 · 2021: $366.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $176.48 | 2020-2021 | |
| Abbvie INC. | $148.61 | 2021 | |
| Allergan, INC. | $139.00 | 2019-2020 | |
| Novo Nordisk INC | $97.05 | 2020-2021 | |
| Lilly USA, LLC | $74.62 | 2020-2021 | |
| Adlon Therapeutics L.P. | $31.48 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $16.17 | 2020 | |
| Daiichi Sankyo INC. | $14.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.55 | 2020 | |
| Dexcom, INC. | $13.29 | 2021 | |
| Amgen INC. | $11.30 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.22 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.